Trial Profile

Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
Indications Adenocarcinoma; Advanced breast cancer
Focus Therapeutic Use
Acronyms INGE-B

10 Mar 2023 Status changed from active, no longer recruiting to completed.
18 Jan 2023 Planned End Date changed from 1 Jan 2023 to 15 Dec 2023.
18 Jan 2023 Planned primary completion date changed from 1 Jan 2023 to 15 Feb 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com